Observational studyClinical cancer research : an official journal of the American Association for Cancer Research2022
A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis.
Observational study in Clinical cancer research : an official journal of the American Association for Cancer Research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02547831 (Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients
Who cites it
30 citing papers in PubMed, 51 citations in OpenAlex.
- Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial.Annals of surgical oncology · 2023Trial
- Review
- Predicting Failure of Active Surveillance in Desmoid-Type Fibromatosis Using Radiomics: An International Multi-center Cohort Study.Annals of surgical oncology · 2026Article
- Local aggressiveness and prognostic prediction in desmoid-type fibromatosis: insights fromAnnals of nuclear medicine · 2026Article
- Percutaneous Management of Desmoid Tumors.Current oncology reports · 2026Review
- Radiologic response assessment in patients with desmoid-type fibromatosis treated with percutaneous cryoablation.European radiology experimental · 2026Article
- Axillary desmoid-type fibromatosis: a rare clinical presentation, histopathological correlation, and literature review.BMC surgery · 2026Review
- Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments.Cancers · 2026Review
- Intra-abdominal aggressive fibromatosis: a single-center case series of 12 patients focusing on surgical management and clinicopathological features.BMC gastroenterology · 2026Article
- Evaluating the impact of surgical resection on desmoid tumour growth: a retrospective analysis from the National Cancer Centre Singapore.Frontiers in surgery · 2026Article
- Surgical Management of Desmoid Tumors-Patient Selection, Timing, and Approach.Current oncology (Toronto, Ont.) · 2025Review
- Sporadic pancreatic desmoid-type fibromatosis with curative resection: A case report.Medicine · 2025Article
- Cryotherapy in the Treatment of Extra-Abdominal Desmoid Tumors-A Review.Current oncology (Toronto, Ont.) · 2025Review
- Active Surveillance in Patients with Extra-abdominal Desmoid-Type Fibromatosis: A Pooled Analysis of Three Prospective Observational Studies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Observational
- Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor.Frontiers in oncology · 2025Article
- Circulating Tumor DNA in Patients with Desmoid Fibromatosis during Active Surveillance.Annals of surgical oncology · 2024Article
- Article
- Mesenchymal Tumor Management: Integrating Surgical and Non-Surgical Strategies in Different Clinical Scenarios.Cancers · 2024Review
- Aggressive fibromatosis of the sigmoid colon: A case report.World journal of gastrointestinal oncology · 2024Article
- PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo prospectively assess the behavior of primary sporadic (not familial adenomatous polyposis-associated) desmoid fibromatosis (DF) managed by active surveillance (AS). EXPERIMENTAL:
designThis is an Italian prospective, multicenter, observational study (NCT02547831) including patients ≥16 years with primary sporadic DF at any site. Patients were assessed by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1. Primary endpoint was progression-free survival (PFS) at 3 years. Treatment-free survival (TFS) was also analyzed. PFS and TFS were calculated by Kaplan-Meier plots and compared by log-rank test. Cox proportional hazard multivariable regression analyses were performed.
resultsFrom 2013 to 2018, 108 consecutive patients were included (82% female); median age was 39 years; median size was 51 mm. CTNNB1 mutations were T41A (50%), S45F (12%), other (19%), wild-type (19%). At 32.3-month median follow-up, 42 of 108 (39%) showed RECIST progression. Spontaneous regression was initially observed in 27 of 108 (25%), while it followed dimensional progression in another 33 of 108 (31%). PFS at 36 months was 54.5% [95% confidence interval (CI), 44.9%-66.1%]. Thirty-five of 108 (32%) patients received active treatment, 18 of 108 (17%) after RECIST progression and 17 of 108 (15%) after symptomatic progression. TFS at 36 months was 65.9% (95% CI, 57.3%-75.9%). Larger tumor size and extremity location were associated to shorter TFS and a trend for S45F mutation was also observed (P = 0.06), while none of the mentioned variables was significantly associated with PFS.
conclusionsIn primary DF, AS can be proposed, because disease stabilization and spontaneous regression frequently occur. However, extra care should be taken for patients with tumors of larger size, extremity location, and S45F mutation. See related commentary by Greene and Van Tine, p. 3911.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.